| Literature DB >> 25642314 |
Babak Rajabi1, John W Sweetenham2.
Abstract
Mantle cell lymphoma as a rare non-Hodgkin B-cell lymphoma can present in different clinical presentations such as an aggressive form or a more indolent picture. Treatment modality is based on multiple factors including age, presence or absence of symptoms, and comorbidities. Watchful waiting is a reasonable approach for asymptomatic patients especially in elderly. In symptomatic patients, treatment is chemo-immunotherapy followed by maintenance immunotherapy or autologous bone marrow transplant. Allogeneic bone marrow transplant has a potential benefit of cure for relapsed/refractory cases, but it has a high mortality rate. Novel treatment with agents such as ibrutinib, a Bruton tyrosine kinase inhibitor, has shown promising results in relapse/refractory cases. We extensively review the most recent data on diagnostic and therapeutic management of mantle cell lymphoma through presenting two extreme clinical scenarios.Entities:
Keywords: chemo-immunotherapy; ibrutinib; mantle cell lymphoma; transplantation
Year: 2015 PMID: 25642314 PMCID: PMC4298490 DOI: 10.1177/2040620714561579
Source DB: PubMed Journal: Ther Adv Hematol ISSN: 2040-6207